 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
BRIEF COMMUNICATIONS |
*Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, "Aldo e Cele Daccò" Villa Camozzi, Ranica, Italy; and Unit of Nephrology, Ospedali Riuniti, Azienda Ospedaliera, Bergamo, Italy.
Correspondence to Dr. Piero Ruggenenti, Clinical Research Center "Aldo e Cele Daccò" Villa Camozzi, "Mario Negri" Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy. Phone: 39-035-319.888; Fax: 39-035-319.331; E-mail: ruggenenti{at}marionegri.it
Abstract
ABSTRACT. In this post hoc, secondary analysis of the Ramipril Efficacy In Nephropathy (REIN) trial, an angiotensin-converting enzyme (ACE) inhibition risk/benefit profile was assessed in 322 patients with nondiabetic, proteinuric chronic nephropathies and different degrees of renal insufficiency. The rate of GFR decline (
GFR) and the incidence of end-stage renal disease (ESRD) during ramipril or non-ACE inhibitor treatment were compared within three tertiles of basal GFR. GFR was comparable in the three tertiles, whereas the incidence of ESRD was higher in the lowest tertile than in the middle and highest tertiles. Ramipril decreased GFR by 22%, 22%, and 35% and the incidence of ESRD by 33% (P < 0.05), 37%, and 100% (P < 0.01) in the lowest, middle, and highest tertiles, respectively. GFR reduction was predicted by basal systolic (P < 0.0001), diastolic (P = 0.02), and mean (P < 0.001) BP and proteinuria (P < 0.0001) but not by basal GFR (P = 0.12). ESRD risk reduction was predicted by basal proteinuria (P < 0.01) and GFR (P < 0.0001) and was strongly dependent on treatment duration (P < 0.0001). Adverse events were comparable among the three tertiles and within each tertile in the two treatment groups. Thus, disease progression and response to ACE inhibition do not depend on severity of renal insufficiency. The risk of ESRD and the absolute number of events saved by ACE inhibition is highest in patients with the lowest GFR. However, renoprotection is maximized when ACE inhibition is started earlier and when long-lasting treatment may result in GFR stabilization and definitive prevention of ESRD.
This article has been cited by other articles:
 |
|
 |
|
  P. P. Dobesh Managing hypertension in patients with type 2 diabetes mellitus. Am. J. Health Syst. Pharm., June 15, 2006; 63(12): 1140 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Bloom, B. L. Jaber, N. E. Madias, F. F. Hou, and X. Zhang Benazepril for advanced chronic renal insufficiency. N. Engl. J. Med., April 6, 2006; 354(14): 1530 - 1531. [Full Text] [PDF]
|
|
|
|
|
|
F. F. Hou, X. Zhang, G. H. Zhang, D. Xie, P. Y. Chen, W. R. Zhang, J. P. Jiang, M. Liang, G. B. Wang, Z. R. Liu, et al. Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency N. Engl. J. Med., January 12, 2006; 354(2): 131 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D.J. Smilde, H. L. Hillege, D. J. van Veldhuisen, and G. Navis Angiotensin-Converting Enzyme Inhibitors and Outcome Among Patients With Heart Failure and Renal Insufficiency: Need for a Prospective Study J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1905 - 1905. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Remuzzi and A. Remuzzi Is Regression of Chronic Nephropathies a Therapeutic Target? J. Am. Soc. Nephrol., April 1, 2005; 16(4): 840 - 842. [Full Text] [PDF]
|
|
|
|
|
|
I. Codreanu, N. Perico, and G. Remuzzi Dual Blockade of the Renin-Angiotensin System: The Ultimate Treatment for Renal Protection? J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S34 - S38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chiurchiu, G. Remuzzi, and P. Ruggenenti Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S58 - S63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. L.M. Esnault, A. Ekhlas, C. Delcroix, M.-G. Moutel, and J.-M. Nguyen Diuretic and Enhanced Sodium Restriction Results in Improved Antiproteinuric Response to RAS Blocking Agents J. Am. Soc. Nephrol., February 1, 2005; 16(2): 474 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Remuzzi, P. Ruggenenti, A. Perna, B. D. Dimitrov, D. de Zeeuw, D. A. Hille, S. Shahinfar, G. W. Carides, B. M. Brenner, and for the RENAAL Study Group Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3117 - 3125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Anavekar, J. J.V. McMurray, E. J. Velazquez, S. D. Solomon, L. Kober, J.-L. Rouleau, H. D. White, R. Nordlander, A. Maggioni, K. Dickstein, et al. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction N. Engl. J. Med., September 23, 2004; 351(13): 1285 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vupputuri, V. Batuman, P. Muntner, L. A. Bazzano, J. J. Lefante, P. K. Whelton, and J. He Effect of Blood Pressure on Early Decline in Kidney Function Among Hypertensive Men Hypertension, December 1, 2003; 42(6): 1144 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. B. Ramirez A Comprehensive Public Health Approach to Address the Burden of Renal Disease in Singapore J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S122 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Hoy, Z. Wang, P. R. A. Baker, and A. M. Kelly Secondary Prevention of Renal and Cardiovascular Disease: Results of a Renal and Cardiovascular Treatment Program in an Australian Aboriginal Community J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S178 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D Laverman, D. de Zeeuw, and G. Navis Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 205 - 213. [Abstract] [PDF]
|
|
|
|
|
|
R. C. Campbell, P. Ruggenenti, and G. Remuzzi Halting the Progression of Chronic Nephropathy J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S190 - 195. [Abstract] [Full Text]
|
|
|
|
|
|
A. Goto, K. A. Brensing, P. Raab, U. Frotscher, G. Remuzzi, A. Schieppati, and P. Ruggenenti Diabetic Nephropathy N. Engl. J. Med., September 19, 2002; 347(12): 947 - 948. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A J Devonald and F. E Karet Targeting the renin-angiotensin system in patients with renal disease J R Soc Med, January 8, 2002; 95(8): 391 - 397. [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
